Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBeijing Zhecheng Biotechnology Co., Ltd.

About this trial

The goal of this clinical trial is to learn whether tart cherry citrate effervescent tablets can lower uric acid levels in people with asymptomatic hyperuricemia (high uric acid levels without gout symptoms).

The main question it aims to answer is:

Does taking tart cherry citrate effervescent tablets lower uric acid levels more effectively than taking a placebo (inactive) tablet, when both groups also receive lifestyle guidance?

Researchers will compare two groups of participants. Both groups will receive lifestyle guidance (advice on diet and exercise). In addition:

* One group will take the tart cherry citrate effervescent tablets. * The other group will take a placebo effervescent tablet (looks and tastes the same but contains no active ingredient).

The study will last 24 weeks.

Participants will:

* Take the assigned effervescent tablet twice daily for 24 weeks * Follow lifestyle guidance for diet and exercise * Attend scheduled clinic visits for checkups and tests * Provide blood and urine samples for testing

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged 18 to 65 years, regardless of sex;

Meet the diagnostic criteria for primary hyperuricemia, with serum urate levels between 420 μmol/L and 540 μmol/L (for those without comorbidities) or between 420 μmol/L and 480 μmol/L (for those with at least one of the following comorbidities: hypertension, dyslipidemia, diabetes mellitus, obesity, stroke, coronary heart disease, heart failure, or CKD stage ≥2);

Participants with asymptomatic hyperuricemia who have not previously received urate-lowering therapy and have no history of acute gout flares;

Voluntarily participate in the study and provide written informed consent.

Disqualifiers

Known allergy to any of the study medications, food products, or their components; current allergies; or known hypersensitivity;

Active liver disease or cirrhosis, or liver dysfunction with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >2 times the upper limit of normal (ULN);

Acute infection or active gastrointestinal ulcers;

History of thyroid dysfunction;

Trial design

Design model

Parallel

Treatments tested in this trial

  • tart cherry citrate effervescent table

    Dietary supplement

    Each effervescent tablet contains tart cherry extract and citrate. Participants take 4.0 g (one tablet) dissolved in 200-250 mL of water twice daily (morning and evening), regardless of meals. Daily total water intake is controlled at 2000-2500 mL. The tablet is taken as an adjunct to lifestyle guidance.

  • Placebo Control Group

    Dietary supplement

    Matching placebo effervescent tablet identical in appearance, taste, and preparation to the tart cherry citrate effervescent tablet but containing no active ingredients. Participants take 4.0 g (one tablet) dissolved in 200-250 mL of water twice daily (morning and evening), regardless of meals. Daily total water intake is controlled at 2000-2500 mL. The tablet is taken as an adjunct to lifestyle guidance.

Treatment groups

196 Participants
are divided into 2 treatment groups
Group A: Tart Cherry Citrate Effervescent TabletExperimental treatment 1 intervention
Group B: Placebo Effervescent TabletPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Difference in serum urate (sUA) levels between groups at week 24

Serum uric acid measured in μmol/L from fasting blood sample.

Time frame
At week 24

Secondary outcomes

1

Difference in serum urate (sUA) levels between groups at each visit

Time frame
At week 12 and week 24
2

Changes in serum urate (sUA) levels within the experimental group before and after intervention

Within-group change in sUA from enrollment to end of treatment.

Time frame
Baseline to Week 24
3

Difference in morning urine pH between groups at week 24

Time frame
At week 24
4

Differences in urine pH (morning urine) between groups at each visit

Time frame
At baseline, week 12, and week 24

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.